Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE Consortium

Neerav Goyal1, Max Hennessy1, Erik Lehman1, Wenxue Lin1, Antonio Agudo2, Wolfgang Ahrens3, Stefania Boccia4a,4b, Paul Brennan5, Hermann Brenner6a,6b,6c, Gabriella Cadoni7a,7b, Cristina Canova8, Chu Chen9, David Conway10, Maria Paula Curado11, Luigino Dal Maso12, Alexander W. Daudt13, Valeria Edefonti14, Eleonora Fabianova15, Leticia Fernandez16, Silvia Franceschi5, Werner Garavello17, Maura Gillison18, Richard B. Hayes19, Claire Healy20, Rolando Herrero5, Ivana Holcatova21, Jossy L. Kanda22, Karl Kelsey23, Bo T. Hansen24, Rosalina Koifman25, Pagona Lagiou26, Carlo La Vecchia14, Fabio Levi27, Guojun Li28, Jolanta Lissowska29, Rossana Mendoza López30, Danièle Luce31, Gary Macfarlane32, Dana Mates33, Keitaro Matsuo34, Michael McClean35, Ana Menezes36, Gwenn Menvielle37, Hal Morgenstern38, Kirsten Moysich39, Eva Negri40, Andrew F. Olshan41, Tamas Pandics42, Jerry Polese12, Mark Purdue43, Loredana Radoi44, Heribert Ramroth45, Lorenzo Richiardi46, Stimson Schantz47, Stephen M. Schwartz9, Diego Serrano12, Oxana Shangina47, Elaine Smith48, Erich M. Sturgis49, Beata Świątkowska50, Peter Thomson51, Thomas L. Vaughan5, Marta Vilensky52, Deborah M. Winn53, Victor Wunsch-Filho54, Guo-Pei Yu55, Jose P. Zevallos56, Zuo-Feng Zhang57, Tongzhang Zheng58, Ariana Znaor5, Paolo Boffetta59a,59b, Mia Hashibe60, Yuan-Chin Amy Lee60, Joshua E Muscat1

1The Pennsylvania State University, College of Medicine, Hershey, PA, USA

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/ODI.14196
Institut Catala Oncologia, Barcelona, Spain
Leibniz Institute for Prevention Research and Epidemiology, BIPS, and University of Bremen, Faculty of Mathematics and Computer Science, Institute of Statistics, Bremen, Germany
Sezione di Igiene, Dipartimento Universitario di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italia.
Department of Woman and Child Health and Public Health - Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia.
International Agency for Research on Cancer, world Health Organization, Lyon, France
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
Dipartimento Scienze dell’Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy;
Dipartimento Patologia Testa Collo e Organi di Senso, Facoltà Medicina e Chirurgia Università Cattolica Sacro Cuore, Roma, Italy;
University of Padua, Padova, Italy
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Dental School, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
Epidemiology- CIPE/ACCAMARGO, Sao Paulo, Brazil
Cancer Epidemiology Unit, Centro di Riferimento Oncologico (CRO) Aviano, IRCCS, Italy
Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
Department of Clinical Sciences and Community Health, University of Milan, Italy
Regional Authority of Public Health in Banska Bystrica, Slovakia
Institute of Oncology and Radiobiology, Havana, Cuba
Department of Otorhinolaryngology, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Division of Epidemiology, New York University School of Medicine, New York, NY, USA
Trinity College School of Dental Science, Dublin, Ireland
21 Institute of Hygiene and Epidemiology, Prague, Czech Republic
22 Faculdade de Medicina do ABC, Hospital de Ensino, São Bernardo do Campo, SP, Brazil
23 Brown University, Providence, RI, USA
24 Cancer Registry of Norway, Oslo, Norway
25 Escola Nacional de Saúde Publica, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil
26 School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
27 Institut Universitaire de Medecine Sociale et Preventive (IUMSP), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
28 UT-M.D. Anderson Cancer Center, Houston, TX, USA
29 M. Sklodowska-Curie National Research Institute of Oncology, Dept. of Cancer Epidemiology and Prevention, Warsaw, Poland
30 Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, Brazil
31 Univ Rennes, INSERM, EHESP, Ierset (Institut de recherche en santé, environnement et travail) - UMR S 1085, Pointe-à-Pitre, France
32 University of Aberdeen Dental School, Aberdeen, UK
33 National Institute of Public Health, Bucharest, Romania
34 Division of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
35 Boston University School of Public Health, Boston, MA, USA
36 Universidade Federal de Pelotas, Pelotas, Brazil
37 INSERM, Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique IPLESP, F75012 Paris, France
38 Departments of Epidemiology and Environmental Health Sciences, School of Public Health and Department of Urology, Medical School, University of Michigan, Ann Arbor, MI, USA
39 Roswell Park Cancer Institute, Buffalo, NY, USA
40 Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
41 University of North Carolina School of Public Health, Chapel Hill, NC, USA
42 National Public Health Center, Budapest, Hungary
43 New York Eye and Ear Infirmary, New York, NY, USA
44 INSERM UMR 1018, Centre for Research in Epidemiology and Population Health (CESP), Cancer Epidemiology, Genes and Environment Team, Villejuif, France
45 Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany
46 University of Turin, Turin, Italy
Cancer Research Centre, Moscow, Russia
College of Public Health, University of Iowa, Iowa City, IA, USA
Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA
Nofer Institute of Occupational Medicine, Lodz, Poland
University of Hong Kong, Hong Kong, China
Institute of Oncology Angel H. Roffo, University of Buenos Aires, Argentina
National Cancer Institute, Bethesda, MD, USA
Universidade de Sao Paulo, Sao Paulo, Brazil
Dept of Otolaryngology, School of Medicine, New York Medical College, Valhalla, New York
Division of Head and Neck Surgical Oncology in the Department of Otolaryngology/Head and Neck Surgery at Washington University School of Medicine, St. Louis, MO, USA
UCLA School of Public Health, Los Angeles, CA, USA
Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA
Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
Division of Public Health, Department of Family & Preventive Medicine and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA


Data Availability Statement: Descriptions of the studies included in the INHANCE Consortium can be found on the database website (http://www.inhance.utah.edu, accessed April 1, 2021).

Funding:
This work was supported by the European Community (5th Framework Programme) grant no QLK1-CT-2001-00182, INHANCE Pooled Data Project: NCI R03CA113157NIDCR R03DE016611 and the Intramural Program of the NCI, NIH, United States. Individual studies were supported by: Aviano study: Italian Association for Research on Cancer (AIRC), Italian League Against Cancer and Italian Ministry of Research; Baltimore study: NIH [DE016631]; Boston study: NIH [R01CA078609, R01CA100679], Central Europe study: World Cancer Research Fund and the European Commission INCO-COPERNICUS Program [Contract No. IC15-CT98-0332]; France 2001-2007 (ICARE): French National Research Agency (ANR); French National Cancer Institute (INCA); French Agency for Food, Environmental and Occupational Health and Safety (ANSES); French Institute for Public Health Surveillance (InVS); Fondation pour la Recherche
Médicale (FRM); Fondation de France; Fondation ARC pour la Recherche sur le Cancer; French Ministry of Labour (Direction Générale du Travail); French Ministry of Health (Direction Générale de la Santé); Germany-Heidelberg study: grant No. 01GB9702/3 from the German Ministry of Education and Research; IARC Multicenter study: Fondo de Investigaciones Sanitarias (FIS) of the Spanish Government [FIS 97/ 0024, FIS 97/0662, BAE 01/5013], International Union Against Cancer (UICC), and Yamagiwa-Yoshida Memorial International Cancer Study Grant; Iowa study: NIH [NIDCR R01DE011979, NIDCR R01DE013110, NIH FIRCA TW001500] and Veterans Affairs Merit Review Funds; Italy multicenter study: Italian Association for Research on Cancer (AIRC), Italian League Against Cancer and Italian Ministry of Research; Japan study (2001-2005): Scientific Research grant from the Ministry of Education, Science, Sports, Culture and Technology of Japan (17015052) and grant for the Third-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare of Japan (H20-002); Latin America study: Fondo para la Investigacion Cientifica y Tecnologica (FONCYT) Argentina, IMIM (Barcelona), Fundaco de Amparo a’ Pesquisa no Estado de Sao Paulo (FAPESP) [No 01/01768-2, 04/12054-9, 10/51168-0], and European Commission [IC18-CT97-0222]; Los Angeles Study: NIH [P50CA090388, R01DA011386, R03CA077954, T32CA009142, U01CA096134, R21ES011667] and the Alper Research Program for Environmental Genomics of the UCLA Jonsson Comprehensive Cancer Center; MSKCC study: NIH [R01CA051845]; Northeast US study: NIH R01DE013158; North Carolina Study: NIH [R01CA061188], & NIEHS [P30ES010126]; NY multicenter study: NIH [P01CA068384 K07CA104231]; Milan study: Italian Association for Research on Cancer (AIRC); Puerto Rico study: jointly funded by National Institutes of Health (NCI) US and NIDCR intramural programs; Rome study: AIRC (Italian Agency for Research on Cancer); Saarland study: Ministry of Science, Research and Arts Baden-Wurttemberg; Seattle study: NIH [R01CA048996, R01DE012609]; Seattle-LEO study: NIH [R01CA030022.

Conflicts of Interest: The authors have no conflicts of interest to disclose

Ethics Approval Statement: Approval was obtained from the institutional review board at the Pennsylvania State University for use of this specific de-identified dataset.

Patient Consent Statement: Informed consent and institutional review board approval were obtained at each study center, and all identifying information was removed before data were transferred for pooling.

Corresponding Author:
Neerav Goyal, MD, MPH
The Pennsylvania State University
College of Medicine
Department of Otolaryngology-Head and Neck Surgery
500 University Drive, H091
Hershey, PA 17033-0850 USA.
Tel #: 717-531-8945
Fax #: 717-531-6160
Email: ngoyal1@pennstatehealth.psu.edu
Abstract

Objective. We analyzed the pooled case-control data from the International Head and Neck Cancer Epidemiology (INHANCE) consortium to compare cigarette smoking and alcohol consumption risk factors for head and neck cancer between less developed and more developed countries.

Subjects and Methods. The location of each study was categorized as either a less developed or more developed country. We compared the risk of overall head and neck cancer and cancer of specific anatomic subsites associated with cigarette smoking and alcohol consumption. Additionally, age and sex distribution between categories was compared.

Results. The odds ratios for head and neck cancer sites associated with smoking duration differed between less developed and more developed countries. Smoking greater than 20 years conferred a higher risk for oral cavity and laryngeal cancer in more developed countries, whereas the risk was greater for oropharynx and hypopharynx cancer in less developed countries. Alcohol consumed for more than 20 years conferred a higher risk for oropharynx, hypopharynx and larynx cancer in less developed countries. The proportion of cases that were young (<45 years) or female differed by country type for some HNC subsites.

Conclusion. These findings suggest the degree of industrialization and economic development affects the relationship between smoking and alcohol with head and neck cancer.
Introduction

Countries can be classified as to development status based on Gross Domestic Product (GDP) per capita, which reflects availability and use of natural resources, degree of industrialization and economic development, quality and access to medical care, and social and economic development\(^1\). On a global basis, per-capita income and economic development differ substantially between less developed and more developed countries (as defined by the United Nations), and this classification has been used as the basis for providing resources to support the economic and social development of developing countries\(^2\). The World Bank has its own classification system by four gross national income groups — high, upper-middle, lower-middle, and low, where lower middle and low incomes are considered less developed countries\(^3\).

Challenges facing less developed countries include rapid urban development, outdoor and indoor air pollution control, crowding, and their associated effects on lifestyle. For example, 92\% of industrial pollution-related deaths occur in low- and middle-income countries and, especially among poorer individuals in all countries\(^4\). Lifestyle contributions to cancer are a major concern, especially as cancer control efforts are substantially underfunded in developing countries that are experiencing aging populations and increased tobacco use in some areas. Many less developed countries lack cancer registries and other rigorously-collected health data, and determining the causes and prevention of cancer has been challenging due to the lack of resources\(^5\).

Head and neck cancer (HNC) is the seventh most common cancer worldwide\(^6\), and its incidence is increasing each year, with an estimated number of 878,348 in 2020\(^7\). For countries with established cancer registries, HNC rates (oral cavity, oropharynx, other HNC) increased from 1983 to 2002 in some countries but decreased in others\(^8\). The 2020 age-standardized rates of oral cavity cancer varied considerably by country. For example, in men the rates were 1.6 per 100,000 in Western Africa and 13.3 per 100,000 in South Central Asia\(^7\). It is projected that future rates will decrease with associated declines in cigarette consumption\(^9\).

The comparative epidemiology of HNC in less and more developed countries is not well documented\(^10\). Tobacco and alcohol use are the major risk factors worldwide, and the population attributable risk of HNC due to tobacco and alcohol in studies conducted in Europe and the Americas is 72\%\(^11\). Other risk factors include low fruit and vegetable intake, poor oral hygiene, hormonal factors, and occupational exposures, as well as the role of genetic variation are not fully characterized\(^12\). Human papillomavirus (HPV) is associated primarily with oropharyngeal HNC.

To determine whether more developed and less developed countries have different risk factor profiles for HNC and HNC subsites, we used pooled data from 32 case-control studies.
The INHANCE Database

The current study included pooled datasets from the INHANCE Consortium (data version 1.5) that contained information on demographic and lifestyle characteristics, including tobacco smoking and alcohol drinking, and tumor information. Descriptions of the studies included in the INHANCE Consortium can be found on the database website (http://www.inhance.utah.edu, accessed April 1, 2021). The dataset for the current analysis included 32 case-control studies, most of which were age and gender frequency-matched; the study populations come from Asia, Europe, North America and South America. The pooling and harmonization methods have been previously described.\textsuperscript{13,14} The majority of cases were classified by ICD-9, ICD-10, or ICD-O codes. This included some cases with overlapping areas of oral cavity and pharynx, who were classified as having overlapping HNC. Informed consent and institutional review board approval were obtained at each study center, and all identifying information was removed before data were transferred for pooling. An approval was also obtained from the institutional review board at the Pennsylvania State University for use of this specific de-identified dataset. Within each study population, subject demographic information and risk factors for HNC were collected by patient questionnaire, trained interviewers, or by the subject’s physicians. Data on each case’s tumor characteristics were obtained from pathology records.

Variable Definitions

Smoking status variables included never, former, and current smokers. We further classified it as Ever (No) and Ever (Yes). Never smokers were classified as Ever (No). Former and current smokers were classified as Ever (Yes). The large sample size enabled us to examine ever smoking history in tumor subsites in the oral cavity and oropharynx (Table 6). For all subjects, descriptive statistics are shown in Table 1. For smoking variables, these included age started and stopped smoking, and mean duration in years. For the binary logistic regression models, duration of smoking was classified into two 20-year intervals (\(\leq 20\) years and \(>20\) years, Table 2). Years of alcohol consumption are shown in Table 1. Alcohol drinking duration in logistic models was also classified into two intervals (\(\leq 20\) years and \(>20\) years). For the variable age, it was modelled as a continuous covariate in most analyses. For table 4, because age was the variable of interest, we classified it as a binary variable (less than 45 vs. older than 45) for our analysis.

Drinking duration in models was classified into two intervals (\(<20\) years, \(>20\) years). Country type (location of the study) was classified as either more developed or less developed, based on United Nations classification.\textsuperscript{15} In the current study, less developed countries included Argentina, Bangladesh, Brazil, China, Cuba, Granada, India, and Sudan. More developed countries included Australia, Canada, Croatia, Greece,
France, Italy, Japan, Spain, Germany, Hungary, Poland, Romania, Russia, Slovakia, the United Kingdom and the United States.

For the main analyses, HNC was grouped into five tumor site categories: oral cavity cancer (OCC), oropharynx cancer (OPC), hypopharynx cancer (HPC), laryngeal cancer (LC), and overlapping HNC. We also conducted a descriptive analysis of smoking prevalence for just oral cavity cancer (OCC) and oropharyngeal cancer (OPC) by their subsites, to explore whether smoking history may further vary by subsite and between more developed and less developed countries.

Statistical Analysis

Descriptive statistics of subject characteristics included means and their standard deviations. Logistic regression models were fit to determine odds ratios (OR) and 95% confidence intervals (95% CI) associated with cigarette smoking years and drinking years, respectively, separately for more developed and less developed countries. In addition to the main effects, a multiplicative interaction term between each of the exposure variables (cigarette smoking years, alcohol consumption years) and country type (more vs less developed) was included in the model. The fits for models with the interaction term with country type were compared to the respective models that did not include the interaction term; the -2 log likelihoods of differences between the two models and corresponding p-values were calculated as tests of the null hypothesis of no multiplicative interaction. Due to overlap between study center and country type, it was not possible to adjust simultaneously for the former. The logistic regression analyses were therefore adjusted for geographic region where each individual study location was assigned to one of four regions (Europe, North America, Central/South America, Asia and other). The risks for HNC and its subsites were adjusted for the age (continuous), sex (categorical), and average cigarettes smoked per day (continuous). The risks associated with cigarette smoking duration were further adjusted for alcohol drinking duration but the findings were similar to the risks that were not adjusted for alcohol drinking. Due to missing data for alcohol duration in some subjects (n=8089 for developed countries, 371 for developing), final models for smoking duration are presented without adjustment for alcohol duration using the full dataset. The analysis for consumption of alcohol was conducted using the same approach, using the dichotomous indicator variable for the categories of alcohol duration to test for interaction with country type.

For the subsite analysis, cases with missing ICD subsite codes, or with codes that indicated unspecified or overlapping subsites were excluded (n=795 for developing counties and 7658 for developed countries). For this analysis, OCCs were grouped into three subcategories including: 1. Gingivo-buccal/hard palate,
retromolar; 2. Oral (anterior) tongue; 3. Floor of mouth. OPCs were subcategorized into: 1. Posterior or base of tongue, 2. Soft palate/oropharyngeal wall; 3. Tonsil. The large INHANCE database was examined for comparing the percent of ever smokers by subsite between developing and developed countries. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Significance was set at a p-value of < 0.05.

Results

The dataset included 25,256 cases and 36,041 controls. Table 1 shows selected characteristics of the subjects including age and sex. About 79% of cases in both groups were men. Mean and median years of smoking in cases were similar between the two groups, whereas mean years of alcohol use was 32 in less developed countries and 36 in more developed countries. Mean BMI was slightly lower in cases than controls for both developing and developed countries, which is consistent with other findings.

Smoking and alcohol on HNC

The association with more than 20 years of cigarette smoking vs. 20 years or less was increased in both more developed (OR=3.8, 95% CI 3.6-4.0) and in less developed countries (OR=2.7, 95% CI 2.4-2.9; interaction p-value <0.0001; Table 2). For alcohol consumption, no differences were found by country development status (Table 3). In the case-only analysis, cases with older age (≥45) were more likely to be associated with developed countries (OR=1.3, 95% CI 1.1-1.4; Table 4). There was evidence of confounding by age. The crude OR was about 1.0 and the age-stratified ORs were both 1.2. The case-only OR for developed countries associated with female sex was 1.2 (95% CI 1.0-1.2; Table 5).

Oral Cavity Cancer (OCC)

The OR for OCC for 20+ years of smoking cigarettes vs ≤20 years was 3.3 (95% CI 3.1-3.6) in more developed counties and 2.0 (95% CI 1.8-2.2) in less developed countries (interaction p-value <0.0001, Table 2). The association of >20 years of alcohol consumption was similar for less and more developed countries (Table 3). In case-only analysis, the OR for developed countries with older age (≥45) was 1.2 (95% CI 1.0-1.4; Table 4). The case-only OR for developed countries associated with female sex was 1.4 (95% CI 1.2-1.5; Table 5).

Oropharyngeal Cancer (OPC)
The odds ratios associated with cigarette smoking >20 years vs. ≤20 years were 5.4 (95% CI 4.4-6.7) in less developed countries and 3.3 (95% CI 3.1-3.6) in more developed countries (Table 2). The association of OPC with >20 years of alcohol use was slightly greater in less developed countries (Table 3). In case-only analysis, the odds ratio for more developed countries associated with female sex was 1.3 (95% CI 1.1-1.6; Table 5).

**Hypopharyngeal Cancer (HC)**

The OR associated with >20 years cigarette smoking vs. ≤20 years was 7.7 (95% CI 5.3-11.3) in less developed countries and 5.8 (95% CI 5.0-6.6) in more developed countries (interaction p-value =0.156; Table 2). The OR for longer duration of alcohol consumption was slightly higher in less developed countries (Table 3). In the case-only analysis, the odds ratio for more developed countries associated with >45 years of age was 1.9 (95% CI, 1.2-2.9, Table 4). The OR was also significantly higher for female sex (Table 5).

**Laryngeal Cancer (LC)**

The positive association between years of smoking cigarettes (>20 vs. < 20 years) was a little stronger in more vs. less developed countries (OR=6.8 vs 4.8, interaction p-value =0.0009; Table 2). The odds ratio for longer alcohol duration was slightly higher in less developed countries (interaction p-value =0.0174; Table 3). The case-only analysis showed that the odds of being a female case were slightly higher in more developed countries (OR=1.3, 95% CI 1.1-1.5; Table 5).

**Overlapping HNC**

The association of smoking cigarettes > 20 years vs. ≤ 20 years was slightly more in more developed vs. less developed countries (interaction p-value =0.021; Table 2). There was no association with alcohol consumption (Table 3, interaction p-value =0.131). In case-only analysis, age and sex were not associated with country type (Tables 4 and 5, respectively).

**Case-series analysis of ever smoking by oral cavity and oropharynx subsite**

Table 6 shows cigarette smoking status (ever vs. never) for more and less developed countries separately for OCC and OPC. As expected, the majority of cases for both subsites were ever smokers. The percent ever smoking was lower for cancers of the gingiva and hard palate (59% for less developed countries and 78% for more developed countries) than other subsites. The proportion of ever smoking was also lower for oral tongue (72.9% for less developed countries and 75.2% for more developed countries) compared to other cancers such as base of tongue. For floor of mouth cancer, ever smoking proportion was 89.2% in less developed countries.
and 94.1% in more developed counties. Within the oropharynx, the site most commonly associated with HPV\textsuperscript{21}, 82.1% and 83.0% of patients with base of tongue cancers were ever smokers in less and more developed countries, respectively.

**Discussion**

We found that the odds ratios associated with >20 years (vs \( \leq 20 \) years) of cigarette smoking was greater in less developed countries for OPC and HPC, whereas >20 years cigarette smoking conferred a greater risk of OC and LC in more developed countries. In contrast, >20 years of alcohol consumption increased the odds of all HNC subsites except OC and overlapping HNC to a greater extent in less developed countries, compared to that in more developed countries.

When considering these findings, several factors need to be considered. There may be different forms or brands of cigarettes that vary by geography. Bidis (tobacco hand-wrapped in plant leaf) are cigarettes commonly used in South and Southeast Asia. They are packaged under different brand names and are often fruit-flavored. Bidis cause OC, HC and LC\textsuperscript{22,23}. Bidis are generally unfiltered and while they contain less tobacco than conventional cigarettes, they emit higher concentrations of tar and nicotine\textsuperscript{24}. INHANCE subjects who might have smoked bidi cigarettes include participants from India and Bangladesh. We did not assess the possible confounding effects of smokeless tobacco products. Chewing of betel quid or “paan” is common in parts of Asia. The areca nut is placed in a betel leaf, often in combination with smokeless tobacco products such as khaini, zarda, mawa in south-central Asia. These products have high concentrations of nitrosamines, and the OPC risk associated with betel nut chewing is about 8 fold when combined with other smokeless tobacco, and about 3 fold when used exclusively\textsuperscript{25,26,27}. Betel quid use information was not routinely collected in INHANCE studies from Asia. The combined association for tobacco smoking and betel quid user is difficult to assess, as betel quid chewers are mostly a subgroup of cigarette smokers in Taiwan. A recent report found no evidence of a greater association than would be expected under either a multiplicative or additive model\textsuperscript{28}. Data from other studies suggest an interactive effect of smoking and chewing\textsuperscript{27,29,30}. The OR for HNC with betel quid use in never tobacco smokers is (OR = 13.71, 95% CI 3.62, 51.92) with a greater effect possibly for OC\textsuperscript{28}.

Likewise, there are smokeless tobacco products used in more developed countries that are not used in less developed countries. INHANCE studies showed that except for the oral cavity, chewing tobacco in the United States was not a risk factor in never smokers and did not modify HNC risk in ever smokers\textsuperscript{31}. Snuff use was associated with a 3-fold risk for OCC in never smokers, but only about 2% of the U.S. study population used snuff, whereas use of the more toxic smokeless product betel quid is common in some less developed populations.
The association of longer vs. shorter duration of alcohol consumption was slightly higher for larynx and pharynx cancer in less developed countries than in more developed countries. In many less developed countries, traditionally and locally prepared beverages are being replaced by internationally-marketed products, especially beer. The risk of HNC did not vary much by beverage type in a previous INHANCE study, although the analysis was limited mostly to European and North American study centers.

BMI was lower in cases than in controls for both developing and developed countries. This is consistent with the literature. In the prospective American Cancer Society Cancer Prevention Study-II, low BMI was associated with HNC mortality but not incidence.

Differences in HPV infection by country type also need to be considered. The attributable fraction of HPV-associated HNC cancer (primarily OPC) has increased in more developed countries compared to less developed countries, particularly in younger men. This is in contrast to the incidence of OCC in the same populations, in which either no change or a decrease in incidence was observed, as would be expected with decreased tobacco use. Many of the INHANCE studies particularly in the more developed countries completed recruitment in the early 2000’s when HPV-positive OPC was less common in more developed countries than it is today. We did not have information on HPV status in most studies and it is unclear from prior research whether there is an excess joint effect of smoking and HPV on OPC risk. Some data indicate an additive effect only, whereas other findings show that the odds ratio associated with heavy smoking is higher in subjects who are HPV seronegative than subjects who are HPV seropositive.

The mean age of HNC at diagnosis was slightly younger in less developed countries, consistent with another report. It has been suggested that the etiology of HNC may differ somewhat in people ages 45 and younger. Our case-only analyses suggested that while some analyses showed departure from multiplicativity between country type and age or sex, the effect was small.

The current study did not measure other factors that are associated with a country’s degree of development or developmental changes. Less developed and more developed countries are defined according to assets, wealth and industrialization. Increasing industrial pollution in less developed countries poses a substantial cancer risk including HNC, with estimates that the incidence of up to 20% of all cancers is due to environmental chemical mixtures. An increasing but still small proportion of cancer deaths in less developed countries are attributable to lifestyle changes including diet and physical inactivity, which have been associated with the risk of HNC.

The current study compares and contrasts overall and subsite-specific associations between tobacco and alcohol use and HNC risk between categories of less and more developed countries. Several INHANCE publications have employed extensive and novel statistical approaches to modeling cigarette smoking and other
exposures including spline and linear-exponential models, demonstrating further variation in risks by HNC subsite46,47. The current study was not designed to recreate those analyses, but to take a first look at comparing the associations as they may vary by country development. We did not control for pipe and cigar smoking, which were previously found not to increase HNC risk in current smokers in the INHANCE data48.

The grouping of countries by level of development is often used as a measure of health disparity, and differs from socioeconomic status (SES) groupings, which is a measure of social position within a defined geographic area49. The SES literature shows that HNC incidence is increased in lower SES relative to higher SES populations in Western countries 50-55. Using the World Bank classification system for developing and developed countries, low SES was associated with oral cancer risk in both high- and lower-income countries.

In a previous INHANCE pooled analysis, low education was associated with an increased risk which was not completely attenuated after adjusting for smoking and alcohol56. The INHANCE consortium pooled data provided the opportunity to examine a different aspect of economic position, namely that which separates countries by wealth, assets and degree of industrialization. It should be noted that Argentina, one of the sites in the current database is classified as a less developed country, although it has an emerging economy that may be more similar to more developed countries.

While INHANCE pooled studies are unique for allowing this type of comparison, there are several limitations. While the INHANCE consortium is large and studies were conducted in many different countries, the data are not a globally representative sample. For example, there is low representation from Africa. The inclusion criteria for age across studies was not uniform, usually defined as >18 or 18-80 years for most studies. This might have biased the age analysis for the case-only comparisons. The case-only analyses are also potentially biased if assumptions of independence between country type and the exposures are violated. This approach is more often used to assess gene-environment interactions, but has potential utility in the current analysis. Misclassification is a concern in case-only analysis but the variables for the current study are well defined. Several (n=13) but not all INHANCE studies had information on oral hygiene risk factors such as tooth loss and gum disease. We were not able to adjust for these variables, although the increased risks with poor hygiene indicators in INHANCE were similar across different geographic regions in a previous report57.

In addition, potential misclassification of HNC subsites needs to be considered when interpreting findings58. The head and neck area is contiguous with boundaries between different sites being somewhat subjective. Some tumors are classified as overlapping but some site misclassification is described in the Surveillance, Epidemiology, and End Results (SEER) database59.

In summary, our analyses of INHANCE data suggest that longer exposure to cigarette smoking and alcohol consumption confer somewhat higher risks among individuals from less developed countries, and
indicate the importance of sustained tobacco control efforts in both developing and developed countries. However, the success of these programs in low SES areas of some developing countries are considered to be dependent on elimination of poverty and improving social inequality.60

References


15. DESA. *World Economic Situation and Prospects 2017.* UN.


59. Fakhry C, Krapcho M, Eisele DW, D'Souza G. Head and neck squamous cell cancers in the United States are rare and the risk now is higher among white individuals compared with black individuals. *Cancer*. 2018;124(10):2125-2133.

Table 1. Selected characteristics of HNC cases and controls from less developed and more developed countries.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall</th>
<th>Cases</th>
<th>Controls</th>
<th>Cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 61,297)</td>
<td>(n = 5,251)</td>
<td>(n = 4,882)</td>
<td>(n = 20,005)</td>
<td>(n = 31,159)</td>
</tr>
<tr>
<td>Mean age (years) *</td>
<td>58.4 ± 11.3</td>
<td>57.7 ± 11.1</td>
<td>55.4 ± 13.3</td>
<td>58.9 ± 10.5</td>
<td>58.5 ± 11.4</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>15410 (25.2%)</td>
<td>1120 (21.4%)</td>
<td>1601 (33.0%)</td>
<td>4269 (21.3%)</td>
<td>8420 (27.0%)</td>
</tr>
<tr>
<td>Male</td>
<td>45842 (74.8%)</td>
<td>4114 (78.6%)</td>
<td>3257 (67.0%)</td>
<td>15734 (78.7%)</td>
<td>22737(73.0%)</td>
</tr>
<tr>
<td>BMI (kg/m$^2$) *</td>
<td>25.1 ± 4.6</td>
<td>22.3 ± 4.4</td>
<td>24.5 ± 4.8</td>
<td>24.6 ± 4.7</td>
<td>25.8 ± 4.4</td>
</tr>
<tr>
<td>Age started smoking (years) *</td>
<td>18.4 ± 5.8</td>
<td>16.6 ± 6.1</td>
<td>17.5 ± 6.4</td>
<td>18.0 ± 5.2</td>
<td>19.26 ± 6.0</td>
</tr>
<tr>
<td>Age stopped smoking (years) *</td>
<td>50.9 ± 13.4</td>
<td>55.0 ± 11.1</td>
<td>48.1 ± 13.7</td>
<td>54.1 ± 12.0</td>
<td>47.7 ± 14.1</td>
</tr>
<tr>
<td>Duration of smoking (years) *</td>
<td>23.0 ±18.9</td>
<td>30.4 ± 19.2</td>
<td>17.2 ±19.0</td>
<td>31.3 ± 16.7</td>
<td>17.4 ± 17.6</td>
</tr>
<tr>
<td>Duration of alcohol use (years) *</td>
<td>33.0 ± 15.6</td>
<td>30.5 ± 16.2</td>
<td>22.4 ± 18.4</td>
<td>35.8 ± 14.0</td>
<td>33.5 ± 15.3</td>
</tr>
</tbody>
</table>

* mean ± standard deviation

INHANCE database
Table 2. Odds ratios for head and neck cancer subtypes by years of smoking, for more developed and less
devolved countries, INHANCE database

<table>
<thead>
<tr>
<th>Head &amp; Neck Cancer site</th>
<th>Country</th>
<th>Smoking Years</th>
<th>N (%)</th>
<th>Odds ratio (95% CI)</th>
<th>Interaction P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>More developed</td>
<td>≤20</td>
<td>4463 (19.9)</td>
<td>Ref</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>15334 (54.1)</td>
<td>3.8 (3.6, 4.0)</td>
<td></td>
</tr>
<tr>
<td>Less developed</td>
<td></td>
<td>≤20</td>
<td>1379 (32.8)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>3760 (65.2)</td>
<td>2.7 (2.4, 2.9)</td>
<td></td>
</tr>
<tr>
<td>Oral cavity</td>
<td>More developed</td>
<td>≤20</td>
<td>1375 (7.1)</td>
<td>Ref</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>3614 (21.7)</td>
<td>3.3 (3.1, 3.6)</td>
<td></td>
</tr>
<tr>
<td>Less developed</td>
<td></td>
<td>≤20</td>
<td>915 (24.5)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>1226 (37.9)</td>
<td>2.0 (1.8, 2.2)</td>
<td></td>
</tr>
<tr>
<td>Oropharynx</td>
<td>More developed</td>
<td>≤20</td>
<td>1422 (7.4)</td>
<td>Ref</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>3942 (23.2)</td>
<td>3.3 (3.1, 3.6)</td>
<td></td>
</tr>
<tr>
<td>Less developed</td>
<td></td>
<td>≤20</td>
<td>125 (4.2)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>718 (26.3)</td>
<td>5.4 (4.4, 6.7)</td>
<td></td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>More developed</td>
<td>≤20</td>
<td>282 (1.6)</td>
<td>Ref</td>
<td>0.1561</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>1618 (11.1)</td>
<td>5.8 (5.0, 6.6)</td>
<td></td>
</tr>
<tr>
<td>Less developed</td>
<td></td>
<td>≤20</td>
<td>30 (1.1)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>304 (13.2)</td>
<td>7.7 (5.3, 11.3)</td>
<td></td>
</tr>
<tr>
<td>Larynx</td>
<td>More developed</td>
<td>≤20</td>
<td>662 (3.6)</td>
<td>Ref</td>
<td>0.0009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>4737 (26.7)</td>
<td>6.8 (6.2, 7.4)</td>
<td></td>
</tr>
<tr>
<td>Less developed</td>
<td></td>
<td>≤20</td>
<td>160 (5.4)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>1124 (35.9)</td>
<td>4.8 (4.0, 5.8)</td>
<td></td>
</tr>
<tr>
<td>Overlapping H&amp;N</td>
<td>More developed</td>
<td>≤20</td>
<td>33 (0.2)</td>
<td>Ref</td>
<td>0.0210</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>142 (1.1)</td>
<td>4.6 (3.1, 6.8)</td>
<td></td>
</tr>
<tr>
<td>Less developed</td>
<td></td>
<td>≤20</td>
<td>37 (1.3)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>119 (5.6)</td>
<td>2.4 (1.6, 3.7)</td>
<td></td>
</tr>
</tbody>
</table>

Adjusted for sex, age, cigarettes per day, and geographic grouping. *Interaction between smoking years and country type.
Table 3. Odds ratios for head and neck cancer subtypes by years of drinking, for more developed and less developed countries, INHANCE database

<table>
<thead>
<tr>
<th>Head &amp; Neck Cancer site</th>
<th>Country</th>
<th>Drinking Years</th>
<th>N (%)</th>
<th>Odds ratio (95% CI)</th>
<th>Interaction P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>More developed</td>
<td>≤20</td>
<td>3643 (27.5)</td>
<td>Ref</td>
<td>0.9030</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>12965 (43.5)</td>
<td>1.7 (1.6, 1.8)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Less developed</td>
<td>≤20</td>
<td>1658 (38.3)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>3377 (62.1)</td>
<td>1.7 (1.5, 1.9)</td>
<td></td>
</tr>
<tr>
<td>Oral cavity</td>
<td>More developed</td>
<td>≤20</td>
<td>1144 (10.6)</td>
<td>Ref</td>
<td>0.4008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>3127 (15.6)</td>
<td>1.6 (1.5, 1.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Less developed</td>
<td>≤20</td>
<td>983 (26.9)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>1112 (35.1)</td>
<td>1.5 (1.5, 1.7)</td>
<td></td>
</tr>
<tr>
<td>Oropharynx</td>
<td>More developed</td>
<td>≤20</td>
<td>948 (9.0)</td>
<td>Ref</td>
<td>0.0115</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>3762 (18.2)</td>
<td>2.0 (1.8, 2.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Less developed</td>
<td>≤20</td>
<td>197 (6.9)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>631 (23.5)</td>
<td>2.6 (2.1, 3.1)</td>
<td></td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>More developed</td>
<td>≤20</td>
<td>195 (2.0)</td>
<td>Ref</td>
<td>0.0240</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>1258 (6.9)</td>
<td>2.5 (2.2, 3.0)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Less developed</td>
<td>≤20</td>
<td>51 (1.9)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>274 (11.7)</td>
<td>3.8 (2.7, 5.2)</td>
<td></td>
</tr>
<tr>
<td>Larynx</td>
<td>More developed</td>
<td>≤20</td>
<td>815 (7.8)</td>
<td>Ref</td>
<td>0.0174</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>3708 (18.0)</td>
<td>1.7 (1.5, 1.8)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Less developed</td>
<td>≤20</td>
<td>279 (9.5)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>976 (32.2)</td>
<td>2.1 (1.8, 2.4)</td>
<td></td>
</tr>
<tr>
<td>Overlapping H&amp;N</td>
<td>More developed</td>
<td>≤20</td>
<td>31 (0.3)</td>
<td>Ref</td>
<td>0.1313</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>129 (0.8)</td>
<td>1.4 (0.9, 2.1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Less developed</td>
<td>≤20</td>
<td>28 (1.0)</td>
<td>Ref</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20</td>
<td>128 (5.9)</td>
<td>2.1 (1.4, 3.4)</td>
<td></td>
</tr>
</tbody>
</table>

Adjusted for sex, age, cigarettes per day, and geographic grouping. *Interaction between drinking years and country type.
Table 4. Case-only odds ratios between age and more developed country status, INHANCE database

<table>
<thead>
<tr>
<th>Cancer site</th>
<th>Age</th>
<th>Country Type</th>
<th>OR</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>More developed</td>
<td>Less developed</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>&lt;45 years</td>
<td>1614 (8.1%)</td>
<td>546 (10.4%)</td>
<td>1.3 (1.1, 1.4)</td>
</tr>
<tr>
<td></td>
<td>≥45 years</td>
<td>18391 (91.9%)</td>
<td>4705 (89.6%)</td>
<td></td>
</tr>
<tr>
<td>Oral cavity</td>
<td>&lt;45 years</td>
<td>501 (10.0%)</td>
<td>287 (13.2%)</td>
<td>1.2 (1.0, 1.4)</td>
</tr>
<tr>
<td></td>
<td>≥45 years</td>
<td>4524 (90.0%)</td>
<td>1887 (86.8%)</td>
<td></td>
</tr>
<tr>
<td>Oropharynx</td>
<td>&lt;45 years</td>
<td>446 (8.3%)</td>
<td>88 (10.2%)</td>
<td>1.3 (1.0, 1.7)</td>
</tr>
<tr>
<td></td>
<td>≥45 years</td>
<td>4951 (91.7%)</td>
<td>775 (89.8%)</td>
<td></td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>&lt;45 years</td>
<td>97 (5.0%)</td>
<td>30 (8.6%)</td>
<td>1.9 (1.2, 2.9)</td>
</tr>
<tr>
<td></td>
<td>≥45 years</td>
<td>1839 (95.0%)</td>
<td>319 (91.4%)</td>
<td></td>
</tr>
<tr>
<td>Larynx</td>
<td>&lt;45 years</td>
<td>280 (5.1%)</td>
<td>71 (5.4%)</td>
<td>1.1 (0.8, 1.4)</td>
</tr>
<tr>
<td></td>
<td>≥45 years</td>
<td>5196 (94.9%)</td>
<td>1250 (94.6%)</td>
<td></td>
</tr>
<tr>
<td>Overlapping H&amp;N</td>
<td>&lt;45 years</td>
<td>16 (9.1%)</td>
<td>21 (13.5%)</td>
<td>1.6 (0.8, 3.2)</td>
</tr>
<tr>
<td></td>
<td>≥45 years</td>
<td>159 (90.9%)</td>
<td>135 (86.5%)</td>
<td></td>
</tr>
</tbody>
</table>

Adjusted for sex and cpd. OR reflects departure from multiplicativity between country type and age.
Table 5. Case-only odds ratios between sex and more developed country status, INHANCE database

<table>
<thead>
<tr>
<th>Cancer site</th>
<th>Gender</th>
<th>Country Type</th>
<th>OR (CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>More developed</td>
<td>Less developed</td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>Male</td>
<td>15734 (78.7%)</td>
<td>4114 (78.6%)</td>
<td>1.2 (1.0, 1.2)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>4269 (21.3%)</td>
<td>1120 (21.4%)</td>
<td></td>
</tr>
<tr>
<td>Oral cavity</td>
<td>Male</td>
<td>3477 (69.2%)</td>
<td>1484 (68.5%)</td>
<td>1.4 (1.2, 1.5)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>1546 (30.8%)</td>
<td>681 (31.5%)</td>
<td></td>
</tr>
<tr>
<td>Oropharynx</td>
<td>Male</td>
<td>4268 (79.1%)</td>
<td>721 (83.7%)</td>
<td>1.3 (1.1, 1.6)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>1129 (20.9%)</td>
<td>140 (16.3%)</td>
<td></td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>Male</td>
<td>1706 (88.2%)</td>
<td>318 (91.1%)</td>
<td>1.5 (1.0, 2.3)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>229 (11.8%)</td>
<td>31 (8.9%)</td>
<td></td>
</tr>
</tbody>
</table>

Adjusted for age and cigarettes per day. OR reflects departure from multiplicativity between country type and gender.
Table 6. Ever smoking status by tumor subsite in oral cavity and oropharynx in less developed and more developed countries, INHANCE database

<table>
<thead>
<tr>
<th>HNC Subsite</th>
<th>Less developed</th>
<th>More developed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**Oral cavity**

Gingivo-buccal/hard palate
- Male: 400 (41.0%) No, 575 (59.0%) Yes
- Female: 352 (22.3%) No, 1226 (77.7%) Yes

Oral tongue
- Male: 191 (27.1%) No, 513 (72.9%) Yes
- Female: 571 (24.8%) No, 1734 (75.2%) Yes

Floor of mouth
- Male: 54 (10.8%) No, 446 (89.2%) Yes
- Female: 78 (5.9%) No, 1246 (94.1%) Yes

**Oropharynx**

Base of tongue
- Male: 64 (17.9%) No, 293 (82.1%) Yes
- Female: 188 (17.0%) No, 917 (83.0%) Yes

Soft palate/oropharyngeal wall
- Male: 15 (6.6%) No, 212 (93.4%) Yes
- Female: 90 (8.8%) No, 938 (91.2%) Yes

Tonsil
- Male: 34 (11.6%) No, 258 (88.4%) Yes
- Female: 230 (15.0%) No, 1311 (85.0%) Yes

Excludes sites not otherwise specified.